Table 2 Comparative table of clinical trials investigating the efficacy of therapies based on glitazones versus gliptins
Reference | N | Treatment | Baseline values for HbA1c [%] | Results | Statistical significance | |
|---|---|---|---|---|---|---|
Glycated hemoglobin HbA1c [%] | Fasting plasma glucose (FPG) [mmol/L] | |||||
Pérez-Monteverde et al., 2011 [20] | 492 | SIT 100 mg |  | −1.0 | −1.48 |  |
PIO 15 mg (30 mg) | −0.9 | −1.56 | ||||
Russell-Jones et al., 2012 [18] | 248 | EQW 2 mg | Ranging from 8.0 to 8.6 across treatment groups | −1.53 | −2.3 | SS |
246 | MET 2000 mg | −1.48 | −2.0 | |||
163 | PIO 45 mg | −1.63 | −2.6 | p < 0.001 | ||
163 | SIT 100 mg | −1.15 | −1.1 | |||
Rosenstock et al., 2007 [19] | 161 | PIO 30 mg | 8.7 ± 1.0 | −1.4 ± 0.1 | −1.9 ± 0.2 | SS |
154 | VIL 100 mg | 8.6 ± 1.0 | −1.1 ± 0.1 | −1.3 ± 0.2 | ||
144 | PIO + VIL 15/50 mg | 8.8 ± 0.9 | −1.7 ± 0.1 | −2.4 ± 0.2 | ||
p < 0.001 | ||||||
148 | PIO + VIL 30/100 mg | 8.8 ± 0.9 | −1.9 ± 0.1 | −2.8 ± 0.2 | ||
Chawla et al., 2013 [25] | 52 | SIT + MET 100/>1500 mg | 8.076 ± 0.722 | −0.656 ± 0.21 | −1.1 | NS P = 0.268 for the between group difference |
PIO + MET 30/>1500 mg | 8.228 ± 0.822 | −0.748 ± 0.35 | −1.7 | |||
Liu et al., 2013 [26] | 60 | SIT + MET + SU 100/≥1500/ half maximal dose |  | −0.71 ± 0.12 | −1.27 ± 0.22 | NS p = 0.16 between group difference for HbA1c |
59 | PIO + MET + SU 30/≥1500/ half maximal dose | −0.94 ± 0.12 | −1.98 ± 0.22 | |||
Bergenstal et al., 2010 [27] | 170 | EQW 2 mg + MET | 8.5 | −1.5 |  | SS p < 0.0001 for EQW vs. SIT; p = 0.0165 for EQW vs. PIO |
172 | PIO 45 mg + MET | −1.2 | ||||
172 | SIT 100 mg + MET | −0.9 | ||||
Lee et al., 2013 [28] | 31 | MET + gliclazide or glimepiride | 8.9 | −2.5 | From 9.24 to 5.71 | SS p < 0.001 for difference in HbA1cfrom baseline for all groups |
30 | MET + PIO 15 mg | 8.8 | −2.8 | From 9.66 to 6.16 | ||
38 | MET + SIT 100 mg | 9.4 | −2.7 | From 9.60 to 5.86 | ||
Blonde et al., 2009 [29] | 1653 | MET + VIL ≥1000/100 mg |  | −0.68 ± 0.02 |  | SS |
825 | MET + TZDs ≥1000 mg | −0.57 ± 0.03 | p = 0.001 | |||
295 | MET + VIL > 1500/100 mg | 8.4 ± 1.0 | −0.88 ± 0.5 | −1.4 ± 0.1 | SS | |
p < 0.001 for all treatment groups at week 52 vs. baseline | ||||||
281 | MET + PIO > 1500/30 mg | 8.4 ± 0.9 | −0.98 ± 0.06 | −2.1 ± 0.1 | ||
Kaur M. et al., 2014 [32] | 30 | MET + VIL 500/50 mg | 8.43 ± 0.75 | −0.75 | −1.75 | SS |
p < 0.001 for all treatment groups vs. baseline | ||||||
30 | MET + PIO 500/15 mg | 8.55 ± 0.84 | −0.85 | −1.85 | ||
30 | VIL + PIO 50/15 mg | 8.56 ± 0.69 | −1.35 | −2.6 | ||
Jindal et al., 2015 [1] | 30 | MET + PIO 1000/30 mg |  | No values, the authors comment that there are not statistically significant differences in the reduction of HbA1c between the two groups | No values, the authors comment that there are not statistically significant differences in the reduction of FPG between the two groups | SS |
p < 0.001 for all treatment groups vs. baseline | ||||||
30 | MET + VIL 1000/100 mg | |||||
Kaur K. et al., 2014 [33] | 25 | PIO 30 mg + MET + SU | 10.93 ± 2.9 | −1.65 | −2.83 | SS |
p < 0.001 for all treatment groups vs. baseline | ||||||
25 | VIL 50 mg + MET + SU | 11.3 ± 0.6 | −1.23 | −3.35 | ||